研究单位：[1]Shanghai Jiao Tong University Affiliated Sixth People's Hospital[2]Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.[3]Beijing Tsinghua Changgung Hospital,Beijing,China[4]Sichuan Academy of Medical Sciences & Sichuan Provincial People''s Hospital,Chengdu,China[5]Sun Yat-sen Memorial Hospital, Sun Yat-sen University,Guangzhou,China[6]Zhujiang Hospital of Southern Medical University,Guangzhusi,China[7]The Fourth Affiliated Hospital of Harbin Medical University,Harbin,China[8]The First People''s Hospital of Yunnan Province,Kunming,China[9]The Second Hospital of Nanjing Medical University,Nanjing,China[10]The Affiliated Qingyuan Hospital ,Guangzhou Medical University（Qingyuan People''s Hospital）,Qingyuan,China[11]The First Hospital of Qinhuangdao,Qinhuangdao,China[12]Shanghai Sixth People''s Hospital Affiliated to Shanghai JiaoTong University,Shanghai,China,200030[13]Shanghai General Hospital,Shanghai,China[14]Tianjin Medical University Chu Hsien-I Memorial Hospital,Tianjin,China[15]Yueyang Central Hospital,Yueyang,China
研究目的：
This study is a multicenter, randomized, double-blind, placebo-controlled Phase IIb clinical trial aimed at evaluating the efficacy, safety, pharmacokinetics (PK), and immunogenicity profile of Efsubaglutide Alfa injection in overweight and obese subjects. The primary endpoint is the percentage change in body weight from baseline after 18 weeks of treatment.
